Chemical compounds from anthropogenic environment and immune evasion mechanisms: Potential interactions

Carcinogenesis

Volumn 36, Issue , 2015, Pages S111-S127

  Kravchenko, Julia ^a   Corsini, Emanuela ^b   Williams, Marc A ^c   Decker, William ^d   Manjili, Masoud H ^e   Otsuki, Takemi ^f   Singh, Neetu ^g   Al Mulla, Faha ^h   Al Temaimi, Rabeah ^h   Amedei, Amedeo ⁱ   Colacci, Anna Maria ^j   Vaccari, Monica ^j   Mondello, Chiara ^k   Ivana Scovassi, A ^k   Raju, Jayadev ^l   Hamid, Roslida A ^m   Memeo, Lorenzo ⁿ   Forte, Stefano ⁿ   Roy, Rabindra ^o   Woodrick, Jordan ^o   Salem, Hosni K ^p   Ryan, Elizabeth P ^q   Brown, Dustin G ^q   Bisson, William H ^r   Lowe, Leroy ^s   Kim Lyerly, H ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c MEDCOM Army Institute of Public Health   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g KING GEORGE'S MEDICAL UNIVERSITY   (India)

^h KUWAIT UNIVERSITY   (Kuwait)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^k CNR   (Italy)

^l TOXICOLOGY RESEARCH DIVISION   (Canada)

^m UNIVERSITY PUTRA MALAYSIA   (Malaysia)

ⁿ Mediterranean Institute of Oncology   (Italy)

^o GEORGETOWN UNIVERSITY   (United States)

^p CAIRO UNIVERSITY   (Egypt)

^q Veterinary Dentistry and Oral Surgery   (United States)

^r OREGON STATE UNIVERSITY   (United States)

^s Getting to Know Cancer   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ATRAZINE; AZAMETHIPHOS; CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIETHYLHEXYLPHTHALATE; ENVIRONMENTAL CHEMICAL; FLUOXASTROBIN; FOCAL ADHESION KINASE; FUNGICIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSECTICIDE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MANEB; PHOSPHATIDYLINOSITOL 3 KINASE; PHTHALIC ACID; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PYRIDABEN; PYROCLOSTROBIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TRICLOSAN; UNCLASSIFIED DRUG; DANGEROUS GOODS;

ANTHROPOGENIC ENVIRONMENT; CARCINOGENESIS; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; GENE TARGETING; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ENVIRONMENT; HAZARDOUS SUBSTANCES; HUMANS; IMMUNE EVASION; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS;

EID: 84937702409     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv033     Document Type: Review

References (278)

1. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
2. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
3. Johnson, J.P. et al. (1989) Tumor immunology: Paul Ehrlich's heritage. Immunol. Today, 10, S35-S37.
4. Decker, W.K. et al. (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev., 20, 271-281.
5. Burdick, C.G. (1937) William Bradley Coley 1862-1936. Ann. Surg., 105, 152.
6. Cann, S.H. et al. (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J., 79, 672-680.
7. Levine, D.B. (2008) The Hospital for the Ruptured and Crippled: William Bradley Coley, third Surgeon-in-Chief 1925-1933. HSS J., 4, 1-9.
8. McCarthy, E.F. (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J., 26, 154-158.
9. Starnes, C.O. (1992) Coley's toxins in perspective. Nature, 357, 11-12.
10. Nauts, H.C. (1989) Bacteria and cancer-antagonisms and benefits. Cancer Surv., 8, 713-723.
11. Thomas, L. (1959) Discussions of Cellular and Humoral Aspects of the Hypersensitive States. Hoeber-Harper, New York, NY.
12. Burnet, F.M. (1970) The concept of immunological surveillance. Prog. Exp. Tumor Res., 13, 1-27.
13. Doherty, P.C. et al. (1975) H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J. Exp. Med., 141, 502-507.
14. Janeway, C.A. et al. (2001) Immunobiology: the Immune System in Health and Disease. Garland Science, Churchill Livingstone, NY.
15. Osada, T. et al. (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother., 57, 1115-1124.
16. Osada, T. et al. (2012) Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin. Oncol., 39, 305-310.
17. Reuben, J.M. et al. (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer, 106, 2437-2444.
18. Gao, Q. et al. (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res., 15, 971-979.
19. Benson, D.M. Jr et al. (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 116, 2286-2294.
20. Vanneman, M. et al. (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer, 12, 237-251.
21. Vajdic, C.M. et al. (2009) Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer, 125, 1747-1754.
22. Vajdic, C.M. et al. (2009) What types of cancers are associated with immune suppression in HIV? Lessons from solid organ transplant recipients. Curr. Opin. HIV AIDS, 4, 35-41.
23. Kirk, G.D. et al. (2007) HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin. Infect. Dis., 45, 103-110.
24. Engels, E.A. et al. (2007) Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res., 67, 6520-6527.
25. Kolb, H.J. et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462-2465.
26. Kolb, H.J. et al.; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
27. Strayer, D.R. et al. (1986) Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity. Breast Cancer Res. Treat., 7, 187-192.
28. Bindea, G. et al. (2010) Natural immunity to cancer in humans. Curr. Opin. Immunol., 22, 215-222.
29. Ferrone, C. et al. (2010) Dual roles for immunity in gastrointestinal cancers. J. Clin. Oncol., 28, 4045-4051.
30. Nelson, B.H. (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol. Rev., 222, 101-116.
31. Pagès, F. et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene, 29, 1093-1102.
32. Prendergast, G.C. (2008) Immune escape as a fundamental trait of cancer:focus on IDO. Oncogene, 27, 3889-3900.
33. de Visser, K.E. et al. (2006) Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 6, 24-37.
34. Triozzi, P.L. et al. (2000) Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer, 89, 2646-2654.
35. Bukur, J. et al. (2003) The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin. Cancer Biol., 13, 353-359.
36. Pistoia, V. et al. (2007) Soluble HLA-G: are they clinically relevant? Semin. Cancer Biol., 17, 469-479.
37. Kmieciak, M. et al. (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur. J. Immunol., 37, 675-685.
38. Santisteban, M. et al. (2009) Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res., 69, 2887-2895.
39. Whiteside, T.L. (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol., 16, 3-15.
40. Knutson, K.L. et al. (2006) IL-2 immunotoxin therapy modulates tumorassociated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol., 177, 84-91.
41. Ferris, R.L. et al. (2005) Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol. Res., 33, 113-133.
42. Meissner, M. et al. (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res., 11, 2552-2560.
43. Cavallo, F. et al. (2011) 2011: the immune hallmarks of cancer. Cancer Immunol. Immunother., 60, 319-326.
44. Whiteside, T.L. (2002) Tumor-induced death of immune cells: its mechanisms and consequences. Semin. Cancer Biol., 12, 43-50.
45. Uotila, P. (1996) The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother., 43, 1-9.
46. Grohmann, U. et al. (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol., 24, 242-248.
47. Muller, A.J. et al. (2007) Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets, 7, 31-40.
48. Rodriguez, P.C. et al. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res., 64, 5839-5849.
49. McKallip, R. et al. (1999) Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol., 163, 3718-3726.
50. Yang, L. et al. (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol., 31, 220-227.
51. Shields, J.D. et al. (2010) Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science, 328, 749-752.
52. Mocellin, S. et al. (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev., 15, 61-76.
53. Vicari, A.P. et al. (2004) Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol. Rev., 202, 223-236.
54. Colombo, M.P. et al. (2007) Regulatory-T-cell inhibition versus depletion:the right choice in cancer immunotherapy. Nat. Rev. Cancer, 7, 880-887.
55. Li, M.O. et al. (2008) TGF-beta: a master of all T cell trades. Cell, 134, 392-404.
56. Cohen, N. et al. (2006) GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood, 107, 2037-2044.
57. Akhurst, R.J. et al. (2001) TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol., 11, S44-S51.
58. Young, M.R. (2004) Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother., 53, 375-382.
59. Balkwill, F. et al. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7, 211-217.
60. Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 5, 263-274.
61. Teng, M.W. et al. (2008) Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol., 84, 988-993.
62. Kim, R. et al. (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology, 121, 1-14.
63. Knutson, K.L. et al. (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J. Immunol., 177, 1526-1533.
64. Reiman, J.M. et al. (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol., 17, 275-287.
65. Zarek, P.E. et al. (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood, 111, 251-259.
66. Waickman, A.T. et al. (2012) Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol. Immunother., 61, 917-926.
67. Zhang, J. et al. (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev., 21, 41-48.
68. Barsoum, I.B. et al. (2011) Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res., 71, 7433-7441.
69. Sugaya, M. (2010) Chemokines and cutaneous lymphoma. J. Dermatol. Sci., 59, 81-85.
70. Yokoyama, W.M. et al. (2003) Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol., 3, 304-316.
71. Creighton, C. et al. (2003) Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol., 3, 301-311.
72. Aldinucci, D. et al. (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol., 221, 248-263.
73. Yuan, J.P. et al. (2004) mRNA expression profiling reveals a role of Helicobacter pylori vacuolating toxin in escaping host defense. World J. Gastroenterol., 10, 1528-1532.
74. Coffelt, S.B. et al. (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta, 1796, 11-18.
75. Gray, A. et al. (2009) Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine, 27(suppl. 6), G52-G59.
76. Iwakiri, D. et al. (2009) Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med., 206, 2091-2099.
77. Pentcheva-Hoang, T. et al. (2004) B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity, 21, 401-413.
78. Yu, H. et al. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 7, 41-51.
79. Park, S.J. et al. (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol., 173, 3844-3854.
80. Sun, R. et al. (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J. Immunol., 172, 5648-5655.
81. Noh, K.H. et al. (2009) Activation of Akt as a mechanism for tumor immune evasion. Mol. Ther., 17, 439-447.
82. Filipov, N.M. et al. (2005) Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. Toxicol. Sci., 84, 139-148.
83. Gollamudi, S. et al. (2012) Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. PLoS One, 7, e36191.
84. Carocci, A. et al. (2011) Melatonin in Parkinson's Disease. Provisional Chapter. Intech. http://cdn.intechopen.com/pdfs-wm/46433.pdf (1 May 2015, date last accessed).
85. Knudsen, T.B. et al. (2011) Disruption of embryonic vascular development in predictive toxicology. Birth Defects Res. C Embryo Today Rev., 93, 312-323.
86. Manfo, F.P.T. et al. (2013) Protective effect of Basella alba and Carpolobia alba extracts against maneb-induced male infertility. Pharmaceut. Biol., 52, 97-104.
87. Qin, R. et al. (2011) Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP+: the involvement of PI3K/Akt pathway activation. Toxicol. Lett., 202, 1-7.
88. Desplats, P. et al. (2012) Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Mol. Neurodegener., 7, 49.
89. Cicchetti, F. et al. (2005) Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol. Dis., 20, 360-371.
90. U.S. EPA. The U.S. Environmental Protection Agency ToxCast Phase I/II Data. http://www.epa.gov/ncct/toxcast/data.html (1 May 2015, date last accessed).
91. Morgan, J.B. et al. (2010) The marine sponge metabolite mycothiazole:a novel prototype mitochondrial complex I inhibitor. Bioorg. Med. Chem., 18, 5988-5994.
92. Kavlock, R. et al. (2012) Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol., 25, 1287-1302.
93. Wallet, M.A. et al. (2013) Triclosan alters antimicrobial and inflammatory responses of epithelial cells. Oral Dis., 19, 296-302.
94. Barros, S.P. et al. (2010) Triclosan inhibition of acute and chronic inflammatory gene pathways. J. Clin. Periodontol., 37, 412-418.
95. Winitthana, T. et al. (2014) Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells. PLoS One, 9, e110851.
96. Ansar Ahmed, S. (2000) The immune system as a potential target for environmental estrogens (endocrine disrupters): a new emerging field. Toxicology, 150, 191-206.
97. Pogribny, I.P. et al. (2013) Environmental toxicants, epigenetics, and cancer. In Epigenetic Alterations in Oncogenesis. Adv. Exp. Med. Biol., 754, 215-232.
98. Cohen, S.M. et al. (2011) Chemical carcinogenesis. Toxicol. Sci., 120(suppl. 1), S76-S92.
99. Holmstrup, M. et al. (2010) Interactions between effects of environmental chemicals and natural stressors: a review. Sci. Total Environ., 408, 3746-3762.
100. Oostingh, G.J. et al. (2008) A high-throughput screening method based on stably transformed human cells was used to determine the immunotoxic effects of fluoranthene and other PAHs. Toxicol. In Vitro, 22, 1301-1310.
101. Oostingh, G.J. et al. (2009) The cytotoxic effects of the organophosphates chlorpyrifos and diazinon differ from their immunomodulating effects. J. Immunotoxicol., 6, 136-145.
102. Röder-Stolinski, C. et al. (2008) Chlorobenzene induces the NF-kappa B and p38 MAP kinase pathways in lung epithelial cells. Inhal. Toxicol., 20, 813-820.
103. Röder-Stolinski, C. et al. (2008) Styrene induces an inflammatory response in human lung epithelial cells via oxidative stress and NFkappaB activation. Toxicol. Appl. Pharmacol., 231, 241-247.
104. Descotes, J. (2006) Methods of evaluating immunotoxicity. Expert Opin. Drug Metab. Toxicol., 2, 249-259.
105. Krzystyniak, K. et al. (1995) Approaches to the evaluation of chemicalinduced immunotoxicity. Environ. Health Perspect., 103, 17.
106. Richter-Reichhelm, H.B. et al. (2002) Workshop report. Children as a special subpopulation: focus on immunotoxicity. Federal Institute for Health Protection of Consumers and Veterinary Medicine (BgVV), 15-16 November 2001, Berlin, Germany. Arch. Toxicol., 76, 377-382.
107. Corsini, E. et al. (2009) Immunotoxicology: opportunities for non-animal test development. Altern. Lab. Anim., 37, 387-397.
108. Luster, M.I. et al. (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam. Appl. Toxicol., 18, 200-210.
109. Luster, M.I. et al. (1993) Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam. Appl. Toxicol., 21, 71-82.
110. Koutros, S. et al. (2010) An update of cancer incidence in the Agricultural Health Study. J. Occup. Environ. Med., 52, 1098-1105.
111. Fredslund, S.O. et al. (2012) Breast cancer in the Arctic-changes over the past decades. Int. J. Circumpolar Health., 71, 19155.
112. Corsini, E. et al. (2013) Pesticide induced immunotoxicity in humans:a comprehensive review of the existing evidence. Toxicology, 307, 123-135.
113. Dietert, R.R. (2008) Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment. J. Immunotoxicol., 5, 401-412.
114. Vinson, F. et al. (2011) Exposure to pesticides and risk of childhood cancer: a meta-analysis of recent epidemiological studies. Occup. Environ. Med., 68, 694-702.
115. Mannetje, A.t. et al. (2012) Farming, growing up on a farm, and haematological cancer mortality. Occup. Environ. Med., 69, 126-132.
116. Enzler, T. et al. (2003) Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med., 197, 1213-1219.
117. Finke, J. et al. (1999) Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today, 20, 158-160.
118. Serafini, P. et al. (2004) High-dose granulocyte-macrophage colonystimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res., 64, 6337-6343.
119. Serafini, P. et al. (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother., 53, 64-72.
120. Korzenik, J.R. et al. (2005) Sargramostim for active Crohn's disease. N. Engl. J. Med., 352, 2193-2201.
121. Curiel, T.J. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10, 942-949.
122. Kuick, R. et al. (2007) Discovery of cancer biomarkers through the use of mouse models. Cancer Lett., 249, 40-48.
123. Gallagher, B. et al. (2001) Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am. J. Epidemiol., 154, 544-556.
124. Frisch, M. et al. (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA, 285, 1736-1745.
125. Biggar, R.J. et al. (2004) Cancer risk in elderly persons with HIV/AIDS. J. Acquir. Immune Defic. Syndr., 36, 861-868.
126. Fung, J.J. et al. (2001) De novo malignancies after liver transplantation:a major cause of late death. Liver Transpl., 7(11 suppl 1), S109-S118.
127. Boshoff, C. et al. (2002) AIDS-related malignancies. Nat. Rev. Cancer, 2, 373-382.
128. Kravchenko, J. et al. (2012) Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. PLoS One, 7, e30736.
129. Strauss, D.C. et al. (2010) Transmission of donor melanoma by organ transplantation. Lancet Oncol., 11, 790-796.
130. Bugelski, P.J. et al. (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int. J. Toxicol., 29, 435-466.
131. Penn, I. (2000) Post-transplant malignancy: the role of immunosuppression. Drug Saf., 23, 101-113.
132. Schug, T.T. et al. (2011) Endocrine disrupting chemicals and disease susceptibility. J. Steroid Biochem. Mol. Biol., 127, 204-215.
133. Germolec, D.R. (2004) Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance. Toxicol. Lett., 149, 109-114.
134. Inoue, A. et al. (2004) Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J. Mol. Endocrinol., 32, 649-661.
135. Laupeze, B. et al. (2002) Polycyclic aromatic hydrocarbons affect functional differentiation and maturation of human monocyte-derived dendritic cells. J. Immunol., 168, 2652-2658.
136. Karrow, N.A. et al. (2005) Oral exposure to atrazine modulates cell-mediated immune function and decreases host resistance to the B16F10 tumor model in female B6C3F1 mice. Toxicology, 209, 15-28.
137. NTP (1994) National Toxicology Program (NTP) Technical Report on the Toxicology and Carcinogenesis Studies of Barium Chloride Dihydrate (CAS no. 10326-27-9) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), NTP TR 432. NIH pub. 94-3163. NTIS pub. PB94-214178. Public Health Service, U.S. Department of Health and Human Services, Research Triangle Park, NC.
138. Pinchuk, L.M. et al. (2007) In vitro atrazine exposure affects the phenotypic and functional maturation of dendritic cells. Toxicol. Appl. Pharmacol., 223, 206-217.
139. Koskinen, W. et al. (1997) Factors Affecting Atrazine Fate in North Central US Soils. Rev. Environ. Contam. Toxicol., 151, 117-165.
140. Dörfler, U. et al. (1997) S-triazine residues in groundwater. Chemosphere, 35, 99-106.
141. Gianessi, L.P. et al. (2000) Pesticide Use in US Crop Production: 1997. National Center for Food and Agricultural Policy, Washington, DC.
142. EPA (2002) Atrazine. HED's Revised Human Health Risk Assessment for the Reregistration Eligibility Decision (RED). U.S. Environmental Protection Agency http://yosemite1.epa.gov/ee/epa/ria.nsf/EIO/F0C9CFBC133BD5AC85256EE000632421 (1 May 2015, date last accessed).
143. Filipov, N.M. et al. (2005) Immunotoxic effects of short-term atrazine exposure in young male C57BL/6 mice. Toxicol. Sci., 86, 324-332.
144. Steinman, R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9, 271-296.
145. Kortenkamp, A. et al. (2011) State of the Art Assessment of Endocrine Disrupters. Final Report, 20, V3. http://ec.europa.eu/environment/chemicals/endocrine/pdf/sota_edc_final_report.pdf (1 May 2015, date last accessed).
146. U.S. EPA (2005) Guidelines for Carcinogen Risk Assessment, EPA/630/P-03/0001b. NCFE Assessment. United States Environmental Protection Agency, Washington, DC.
147. Vandenberg, L.N. et al. (2012) Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr. Rev., 33, 378-455.
148. Wild, C.P. et al. (2013) Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ. Mol. Mutagen., 54, 480-499.
149. Pavanello, S. et al. (2012) Biological monitoring of carcinogens: current status and perspectives. Arch. Toxicol., 86, 535-541.
150. Kravchenko, J. et al. (2011) Breast cancer as heterogeneous disease:contributing factors and carcinogenesis mechanisms. Breast Cancer Res. Treat., 128, 483-493.
151. Manton, K.G. et al. (2009) Cancer Mortality and Morbidity Patterns in the US Population: An Interdisciplinary Approach. Springer, New York, NY.
152. DHHS (2009) Fourth National Report on Human Exposure to Environmental Chemicals. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 520 p. http://www. cdc.gov/exposurereport/pdf/fourthreport.pdf (1 May 2015, date last accessed).
153. DHHS (2013) Fourth National Report on Human Exposure to Environmental Chemicals. Updated Tables, March 2013. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 324 p. http://www.cdc.gov/exposurereport/pdf/FourthReport_ UpdatedTables_Mar2013.pdf (1 May 2015, date last accessed).
154. DHHS (2014) Fourth National Report on Human Exposure to Environmental Chemicals. Updated Tables, August 2014. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. http://www.cdc.gov/exposurereport/pdf/fourthreport_updatedtables_ aug2014.pdf (1 May 2015, date last accessed).
155. IARC (2013) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Agents Classified by the IARC Monographs. International Agency for Research and Cancer, Lyon.
156. Martin, M.T. et al. (2010) Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol., 23, 578-590.
157. Wallace, A.D. (2012) Toxic endpoints in the study of human exposure to environmental chemicals. Prog. Mol. Biol. Transl. Sci., 112, 89.
158. Houck, K.A. et al. (2009) Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen, 14, 1054-1066.
159. Kleinstreuer, N.C. et al. (2013) In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. Toxicol. Sci., 131, 40-55.
160. Kaminsky, D.E. et al. (2008) Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes. J. Neuroimmune Pharmacol., 3, 75-82.
161. Meek, M. et al. (2011) Risk assessment of combined exposure to multiple chemicals: a WHO/IPCS framework. Regul. Toxicol. Pharmacol., 60, S1-S14.
162. Blaauboer, B.J. (2010) Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health B Crit. Rev., 13, 242-252.
163. Rotroff, D.M. et al. (2010) Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci., 117, 348-358.
164. Wetmore, B.A. et al. (2012) Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci., 125, 157-174.
165. Khatami, M. (2011) Unresolved inflammation: 'immune tsunami' or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Expert Opin. Biol. Ther., 11, 1419-1432.
166. Khatami, M. (2008) 'Yin and Yang' in inflammation: duality in innate immune cell function and tumorigenesis. Expert Opin. Biol. Ther., 8, 1461-1472.
167. Puskas, L. et al. (2005) Gene expression in thyroid tumors. In Farid, N.R. (ed) Molecular Basis of Thyroid Cancer. Vol. 122, pp. 265-271.
168. Keir, M.E. et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol., 26, 677-704.
169. Cappello, P. et al. (2009) An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int. J. Cancer, 125, 639-648.
170. Chang, G.C. et al. (2006) Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin. Cancer Res., 12, 5746-5754.
171. Takashima, M. et al. (2005) Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics, 5, 1686-1692.
172. Cappello, P. et al. (2013) Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology, 144, 1098-1106.
173. Amedei, A. et al. (2013) Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol. Immunother., 62, 1249-1260.
174. Amedei, A. et al. (2014) Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum. Vaccin. Immunother, 10, 3354-3368.
175. Yang, S.N. et al. (2014) The effects of environmental toxins on allergic inflammation. Allergy Asthma Immunol. Res., 6, 478-484.
176. Dietert, R.R. et al. (2010) Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. Environ. Health Perspect., 118, 1091-1099.
177. Kuo, P.L. et al. (2011) Ginger suppresses phthalate ester-induced airway remodeling. J. Agric. Food Chem., 59, 3429-3438.
178. Kuo, C.H. et al. (2012) Immunomodulatory effects of environmental endocrine disrupting chemicals. Kaohsiung J. Med. Sci., 28(7 suppl.), S37-S42.
179. Veiga-Lopez, A. et al. (2013) Developmental programming: gestational bisphenol-A treatment alters trajectory of fetal ovarian gene expression. Endocrinology, 154, 1873-1884.
180. Abi Salloum, B. et al. (2013) Developmental programming: impact of prenatal exposure to bisphenol-A and methoxychlor on steroid feedbacks in sheep. Toxicol. Appl. Pharmacol., 268, 300-308.
181. Wei, J. et al. (2011) Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a highfat diet. Endocrinology, 152, 3049-3061.
182. Alonso-Magdalena, P. et al. (2010) Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ. Health Perspect., 118, 1243-1250.
183. Maestrelli, P. et al. (2009) Mechanisms of occupational asthma. J. Allergy Clin. Immunol., 123, 531-542; quiz 543.
184. Vawda, S. et al. (2014) Associations between inflammatory and immune response genes and adverse respiratory outcomes following exposure to outdoor air pollution: a HuGE systematic review. Am. J. Epidemiol., 179, 432-442.
185. Clayton, R. et al. (2010) The impact of bisphenol A and triclosan on immune parameters in the U. S. Population, NHANES 2003 a 2006. Environ. Health Perspect., 119, 390-396.
186. Heemskerk, V.H. et al. (1999) Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev., 10, 5-14.
187. Kim, J.H. et al. (2013) Synergism of antifungal activity between mitochondrial respiration inhibitors and kojic acid. Molecules, 18, 1564-1581.
188. Çayi{dotless}r, A. et al. (2012) Micronuclei, nucleoplasmic bridges, and nuclear buds induced in human lymphocytes by the fungicide signum and its active ingredients (boscalid and pyraclostrobin). Environ. Toxicol, 29, 723-732.
189. Bartlett, D.W. et al. (2002) The strobilurin fungicides. Pest Manage. Sci., 58, 649-662.
190. Judson, R.S. et al. (2010) In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. (Online), 118, 485.
191. Maltby, L. et al. (2009) Fungicide risk assessment for aquatic ecosystems:importance of interspecific variation, toxic mode of action, and exposure regime. Environ. Sci. Technol., 43, 7556-7563.
192. Pereboeva, L. et al. (2013) DNA damage responses and oxidative stress in dyskeratosis congenita. PLoS One, 8, e76473.
193. Shadnia, S. et al. (2005) Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum. Exp. Toxicol., 24, 439-445.
194. Navarro, A. et al. (2010) Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity. J. Bioenerg. Biomembr., 42, 405-412.
195. Ratner, V. et al. (2009) Mitochondrial dysfunction contributes to alveolar developmental arrest in hyperoxia-exposed mice. Am. J. Respir. Cell Mol. Biol., 40, 511-518.
196. Boyd, J. et al. (2011) Exploring the boundaries of additivity: mixtures of NADH: quinone oxidoreductase inhibitors. Chem. Res. Toxicol., 24, 1242-1250.
197. Kleinstreuer, N.C. et al. (2011) Environmental impact on vascular development predicted by high-throughput screening. Environ. Health Perspect., 119, 1596.
198. Bloom, S.E. et al. (2006) Potentiation of apoptosis by heat stress plus pesticide exposure in stress resistant human B-lymphoma cells and its attenuation through interaction with follicular dendritic cells: role for c-Jun N-terminal kinase signaling. Toxicol. Sci., 89, 214-223.
199. Muscarella, D.E. et al. (2003) Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite-and pesticideinduced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol. Sci., 74, 66-73.
200. Fang, N. et al. (1998) Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH: ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc. Natl Acad. Sci. USA, 95, 3380-3384.
201. Rowlands, J.C. et al. (1998) NADH: ubiquinone oxidoreductase inhibitors block induction of ornithine decarboxylase activity in MCF-7 human breast cancer cells*. Pharmacol. Toxicol., 83, 214-219.
202. Dixit, A. et al. (2013) Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. Biochim. Biophys. Acta, 1832, 1227-1240.
203. Santos, P.M. et al. (2009) Insights into yeast adaptive response to the agricultural fungicide mancozeb: a toxicoproteomics approach. Proteomics, 9, 657-670.
204. Valentich, M.A. et al. (1996) Expression of dynamin immunoreactivity in experimental pancreatic tumors induced in rat by mancozebnitrosomethylurea. Cancer Lett., 102, 23-29.
205. Grosicka-Maciąg, E. et al. (2011) Protective effect of N-acetyl-Lcysteine against maneb induced oxidative and apoptotic injury in Chinese hamster V79 cells. Food Chem. Toxicol., 49, 1020-1025.
206. Tyagi, S. et al. (2011) Neoplastic alterations induced in mammalian skin following mancozeb exposure using in vivo and in vitro models. OMICS, 15, 155-167.
207. Litteljohn, D. et al. (2010) Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinson's Dis., 2011, 713517. doi:10.4061/2011/713517.
208. Osaba, L. et al. (2002) Evaluation of genotoxicity of captan, maneb and zineb in the wing spot test of Drosophila melanogaster: role of nitrosation. Mutat. Res. Genet. Toxicol. Environ. Mutagen., 518, 95-106.
209. Van Maanen, J. et al. (1995) Modulation of nitrate-nitrite conversion in the oral cavity. Cancer Detect. Prev., 20, 590-596.
210. Vandhana, S. et al. (2013) Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim. Biophys. Acta, 1831, 1458-1466.
211. Paul, K.B. et al. (2013) Cross-species analysis of thyroperoxidase inhibition by xenobiotics demonstrates conservation of response between pig and rat. Toxicology, 312, 97-107.
212. Zuckerbraun, H.L. et al. (1998) Triclosan, cytotoxicity, mode of action, and induction of apoptosis in human gingival cells in vitro. Eur. J. Oral Sci., 106, 628-636.
213. Gee, R. et al. (2008) Oestrogenic and androgenic activity of triclosan in breast cancer cells. J. Appl. Toxicol., 28, 78-91.
214. Tamura, I. et al. (2012) Triclosan, an antibacterial agent, increases intracellular Zn2+ concentration in rat thymocytes: its relation to oxidative stress. Chemosphere, 86, 70-75.
215. Cullinan, M.P. et al. (2012) Long term use of triclosan toothpaste and thyroid function. Sci. Total Environ., 416, 75-79.
216. Peighambarzadeh, S. et al. (2011) Presence of atrazine in the biological samples of cattle and its consequence adversity in human health. Iran. J. Public Health, 40, 112.
217. Zaya, R.M. et al. (2011) Exposure to atrazine affects the expression of key genes in metabolic pathways integral to energy homeostasis in Xenopus laevis tadpoles. Aquat. Toxicol., 104, 254-262.
218. Manske, M.K. et al. (2004) Low-level atrazine exposure decreases cell proliferation in human fibroblasts. Arch. Environ. Contam. Toxicol., 46, 438-444.
219. Albanito, L. et al. (2008) G-protein-coupled receptor 30 and estrogen receptor-α are involved in the proliferative effects induced by atrazine in ovarian cancer cells-RETRACTED. Environ. Health Perspect., 116, 1648.
220. Ueda, M. et al. (2005) Possible enhancing effects of atrazine on growth of 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. Cancer Sci., 96, 19-25.
221. Wetzel, L.T. et al. (1994) Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. J. Toxicol. Environ. Health A Curr. Issues, 43, 169-182.
222. Lim, S. et al. (2009) Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One, 4, e5186.
223. Kandori, H. et al. (2005) Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Sci., 96, 221-226.
224. Jiang, Y. et al. (2013) Prenatal exposure to bisphenol A at the reference dose impairs mitochondria in the heart of neonatal rats. J. Appl. Toxicol, 34, 1012-1022.
225. Lee, H.-S. et al. (2012) Set, a putative oncogene, as a biomarker for prenatal exposure to bisphenol A. Asian Pac. J. Cancer Prev., 13, 2711-2715.
226. Betancourt, A.M. et al. (2012) Altered carcinogenesis and proteome in mammary glands of rats after prepubertal exposures to the hormonally active chemicals bisphenol a and genistein. J. Nutr., 142, 1382S-1388S.
227. Fillon, M. (2012) Getting it right: BPA and the difficulty proving environmental cancer risks. J. Natl Cancer Inst., 104, 652-655.
228. Durando, M. et al. (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J. Steroid Biochem. Mol. Biol., 127, 35-43.
229. Allard, P. et al. (2010) Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. Proc. Natl Acad. Sci. USA, 107, 20405-20410.
230. Terasaka, H. et al. (2005) Cytotoxicity and apoptosis-inducing activity of bisphenol A and hydroquinone in HL-60 cells. Anticancer Res., 25, 2241-2247.
231. Xu, J. et al. (2002) Bisphenol A induces apoptosis and G2-to-M arrest of ovarian granulosa cells. Biochem. Biophys. Res. Commun., 292, 456-462.
232. Goodson, W.H. et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733.
233. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis, 34, 703-712.
234. Pupo, M. et al. (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer- associated fibroblasts. Environ. Health Perspect., 120, 1177-1182.
235. Wang, H. et al. (2013) Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of Snail in colorectal cancer. PloS One, 8, e56664.
236. Wu, C.-H. et al. (2012) Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation. J. Biol. Chem., 287, 25292-25302.
237. Graham, C.H. et al. (1999) Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer, 80, 617-623.
238. Feng, Y. et al. (2012) Bisphenol AF may cause testosterone reduction by directly affecting testis function in adult male rats. Toxicology Lett., 211, 201-209.
239. Ryu, J.Y. et al. (2007) Di (2-ethylhexyl) phthalate induces apoptosis through peroxisome proliferators-activated receptor-gamma and ERK 1/2 activation in testis of Sprague-Dawley rats. J. Toxicol. Environ. Health Part A, 70, 1296-1303.
240. Lin, C.-H. et al. (2011) Activation of Trim17 by PPARγ is involved in Di (2-ethylhexyl) phthalate (DEHP)-induced apoptosis on Neuro-2a cells. Toxicol. Lett., 206, 245-251.
241. James, N.H. et al. (1998) Suppression of hepatocyte apoptosis and induction of DNA synthesis by the rat and mouse hepatocarcinogen diethylhexylphlathate (DEHP) and the mouse hepatocarcinogen 1, 4-dichlorobenzene (DCB). Arch. Toxicol., 72, 784-790.
242. Rusyn, I. et al. (2006) Modes of action and species-specific effects of di-(2-ethylhexyl) phthalate in the liver. CRC Crit. Rev. Toxicol., 36, 459-479.
243. Hsieh, T.-H. et al. (2012) Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. FASEB J., 26, 778-787.
244. Park, M.-A. et al. (2012) Cell growth of BG-1 ovarian cancer cells is promoted by di-n-butyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes. Mol. Med. Rep., 5, 761-766.
245. Moushumi Priya, A. et al. (2012) Induction of apoptosis and cell cycle arrest by Bis (2-ethylhexyl) phthalate produced by marine Bacillus pumilus MB 40. Chem. Biol. Interact., 195, 133-143.
246. Erkekoğlu, P. et al. (2011) Induction of ROS, p53, p21 in DEHP-and MEHP-exposed LNCaP cells-protection by selenium compounds. Food Chem. Toxicol., 49, 1565-1571.
247. Erkekoglu, P. et al. (2010) Evaluation of cytotoxicity and oxidative DNA damaging effects of di (2-ethylhexyl)-phthalate (DEHP) and mono (2-ethylhexyl)-phthalate (MEHP) on MA-10 Leydig cells and protection by selenium. Toxicol. Appl. Pharmacol., 248, 52-62.
248. Isenberg, J.S. et al. (2001) Reversibility and persistence of di-2-ethylhexyl phthalate (DEHP)-and phenobarbital-induced hepatocellular changes in rodents. Toxicol. Sci., 64, 192-199.
249. Rao, K.N. et al. (1997) Hepatic hyperplasia and cancer in rats: metabolic alterations associated with cell growth. Gastroenterology, 113, 238-248.
250. U.S. EPA (2000) List of Chemicals Evaluated for Carcinogenic Potential. U.S. EPA http://www.epa.gov/pesticides/carlist/ (1 May 2015, date last accessed).
251. Odermatt, A. et al. (2008) Disruption of glucocorticoid and mineralocorticoid receptor-mediated responses by environmental chemicals. CHIMIA Int. J. Chem., 62, 335-339.
252. U.S. EPA (2005) Maneb Facts. Prevention, Pesticides and Toxic Substances (7508C). EPA 738-F-05_XX. U.S. EPA http://www.epa.gov/opp00001/reregistration/REDs/factsheets/maneb_fact.pdf (1 May 2015, date last accessed).
253. NPIC (1996) Maneb. Extension Toxicology Network. Pesticide Information Profiles. NPIC http://extoxnet.orst.edu/pips/maneb.htm (1 May 2015, date last accessed).
254. Kuster, M. et al. (2009) Liquid chromatography-tandem mass spectrometric analysis and regulatory issues of polar pesticides in natural and treated waters. J. Chromatogr. A, 1216, 520-529.
255. Miller, S.M. et al. (2000) Atrazine and nutrients in precipitation: results from the Lake Michigan mass balance study. Environ. Sci. Technol., 34, 55-61.
256. Fenelon, J. et al. (1998) Transport of agrichemicals to ground and surface water in a small central Indiana watershed. J. Environ. Qual., 27, 884-894.
257. Stoker, T.E. et al. (1999) Maternal exposure to atrazine during lactation suppresses suckling-induced prolactin release and results in prostatitis in the adult offspring. Toxicol. Sci., 52, 68-79.
258. Fan, W. et al. (2007) Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ. Health Perspect., 115, 720-727.
259. Martin, M.T. et al. (2011) Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol. Reprod., 85, 327-339.
260. Metzler, M. et al. (2001) Chemistry of natural and anthropogenic endocrine active compounds. In Endocrine Disruptors-Part I. The Handbook of Environmental Chemistry. Vol. 3L, pp. 63-80.
261. Boyd, G.R. et al. (2003) Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. Sci. Total Environ., 311, 135-149.
262. Kolpin, D.W. et al. (2002) Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol., 36, 1202-1211.
263. Gatidou, G. et al. (2007) Simultaneous determination of the endocrine disrupting compounds nonylphenol, nonylphenol ethoxylates, triclosan and bisphenol A in wastewater and sewage sludge by gas chromatography-mass spectrometry. J. Chromatogr. A, 1138, 32-41.
264. Foran, C.M. et al. (2000) Developmental evaluation of a potential nonsteroidal estrogen: triclosan. Mar. Environ. Res., 50, 153-156.
265. Ishibashi, H. et al. (2004) Effects of triclosan on the early life stages and reproduction of medaka Oryzias latipes and induction of hepatic vitellogenin. Aquat. Toxicol., 67, 167-179.
266. NICNAS (2006) Diethylhexyl Phthalate (DEHP) Factsheet. CAS: 117-81-7. NICNAS.
267. Jobling, S. et al. (1995) A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ. Health Perspect., 103, 582-587.
268. Hao, C. et al. (2013) Perinatal exposure to diethyl-hexyl-phthalate induces obesity in mice. Front. Biosci. (Elite Ed.), 5, 725-733.
269. IARC (1982) Monograph on the Evaluation of Carcinogenic Risk to Humans. Some Industrial Chemicals and Dyestuffs. Di(2-ethylhexyl) Phthalate. International Agency for Research and Cancer, Lyon.
270. IARC (2000) Monograph on the Evaluation of Carcinogenic Risk to Humans. Some Industrial Chemicals. Di(2-ethylhexyl) Phthalate. International Agency for Research and Cancer, Lyon, pp. 41-148.
271. Tomasetti, C. et al. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science, 347, 78-81.
272. Bisson, W.H. (2012) Editorial: computational chemogenomics in drug design and discovery. Curr. Top. Med. Chem., 12, 1867-1868.
273. Akushevich, I. et al. (2012) New stochastic carcinogenesis model with covariates: an approach involving intracellular barrier mechanisms. Math. Biosci., 236, 16-30.
274. Moolgavkar, S.H. et al. (1981) Mutation and cancer: a model for human carcinogenesis. J. Natl Cancer Inst., 66, 1037-1052.
275. Tan, W.-Y. (1991) Stochastic Models for Carcinogenesis. CRC Press Series:Statistics: A Series of Textbooks and Monographs. Vol. 116. Marcel Dekker, Inc. New York, Basel, Hong Kong. pp. 264.
276. Luebeck, E.G. et al. (2002) Multistage carcinogenesis and the incidence of colorectal cancer. Proc. Natl Acad. Sci. USA., 99, 15095-15100.
277. Little, M.P. et al. (2003) A stochastic carcinogenesis model incorporating genomic instability fitted to colon cancer data. Math. Biosci., 183, 111-134.
278. Kravchenko, J. et al. (2012) Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. PLoS One, 7, e37430.